Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Piramal Pharma Limited ( (IN:PPLPHARMA) ) just unveiled an update.
Piramal Pharma Limited’s board has approved the audited standalone and consolidated financial statements and results for the quarter and full year ended 31 March 2026, in line with SEBI listing requirements. The company plans to publish these results in newspapers, reinforcing regulatory compliance and transparency for investors.
The board also cleared a slate of re-appointments, including extending the tenure of Executive Director and Chairperson Nandini Piramal from April 2027 and Executive Director Peter DeYoung from October 2026, both subject to shareholder approval. Independent directors Sridhar Gorthi and Peter Stevenson were re-appointed for second five-year terms from March 2027, moves that signal continuity in leadership and governance for stakeholders.
More about Piramal Pharma Limited
Piramal Pharma Limited is an India-based pharmaceutical company engaged in developing and manufacturing a range of pharma products and solutions. The company operates in the broader healthcare and life sciences industry, serving global and domestic markets through its diversified pharmaceutical offerings.
Average Trading Volume: 217,020
Technical Sentiment Signal: Hold
Current Market Cap: 219.9B INR
Learn more about PPLPHARMA stock on TipRanks’ Stock Analysis page.